Prior notification of a concentration

(Case M.9461 — AbbVie/Allergan)

(Text with EEA relevance)

(2019/C 392/11)

1. On 12 November 2019, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 [1].

This notification concerns the following undertakings:

— AbbVie Inc., ('AbbVie', United States),

— Allergan plc ('Allergan', Ireland).

AbbVie acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of Allergan.

The concentration is accomplished by way of purchase of shares.

2. The business activities of the undertakings concerned are:

— AbbVie is a global pharmaceutical company listed on the New York Stock Exchange and headquartered in the United States. AbbVie is engaged in the development and commercialisation of innovative medicines in six main therapeutic areas: immunology (including autoimmune diseases), oncology, virology, neuroscience/central nervous system disorders, metabolic diseases and pain associated with endometriosis;

— Allergan is a global pharmaceutical company listed on the New York Stock Exchange and headquartered in Ireland. Allergan is engaged in the development and commercialisation of medicines in four key therapeutic areas: medical aesthetics, eye care, neuroscience/central nervous system disorders and gastroenterology.

3. On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

4. The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.9461 — AbbVie/Allergan

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301

Postal address:

European Commission
Directorate-General for Competition
Merger Registry
1049 Bruxelles/Brussel
BELGIQUE/BELGIË

---

[1] OJ L 24, 29.1.2004, p. 1 (the 'Merger Regulation').